{
  "title": "Paper_236",
  "abstract": "pmc Sci Rep Sci Rep 1579 scirep Scientific Reports 2045-2322 Nature Publishing Group PMC12491499 PMC12491499.1 12491499 12491499 41039037 10.1038/s41598-025-17562-5 17562 1 Article Exploration of isolated actives from Coleus amboinicus Gurning Kasta 1 2 Kurniawan Yehezkiel Steven 1 Silitonga Friska Septiani 1 3 Primahana Gian 4 Astuti Endang 1 Haryadi Winarto wnrt_haryadi@ugm.ac.id 1 1 https://ror.org/03ke6d638 grid.8570.a 0000 0001 2152 4506 Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Gadjah Mada Yogyakarta, 2 3 https://ror.org/01ktt4j08 grid.444553.7 0000 0004 0386 4947 Department of Chemistry, Faculty of Engineering and Maritime Technology, Universitas Maritim Raja Ali Haji, 4 https://ror.org/02hmjzt55 National Research and Innovation Agency (BRIN), Research Center for Pharmaceutical Ingredients and Traditional Medicine, 2 10 2025 2025 15 478255 34445 27 5 2025 25 8 2025 02 10 2025 04 10 2025 04 10 2025 © The Author(s) 2025 2025 https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access http://creativecommons.org/licenses/by-nc-nd/4.0/ Cancer is one of the serious health problems and is a major cause of death worldwide. Therefore, the development of anticancer agents is urgently needed. A potential and novel anticancer agent was successfully isolated from Coleus amboinicus C. amboinicus 50 50 50 Supplementary Information The online version contains supplementary material available at 10.1038/s41598-025-17562-5. Keywords Coleus amboinicus Breast cancer NSCLC Cervical cancer Prostate cancer Pathway in cancer Subject terms Biotechnology Cancer Plant sciences Molecular medicine pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes issue-copyright-statement © Springer Nature Limited 2025 Introduction Coleus amboinicus Lamiaceae 1 2 1 3 1 3 7 The diverse therapeutic effects, especially in the development of potential anticancer agents, encourage the isolation of bioactive compounds from the leaf parts of this plant and the exploration of the potential cytotoxic activity as anticancer agents. Previous studies have successfully isolated royleanone derivative compounds from the leaf parts of Coleus amboinicus C. amboinicus syn O 2 8 9 O 10 9 11 Cytotoxic testing is carried out as an initial assay regarding the potential activity of compounds against target diseases and to estimate the side effects caused. In addition, cytotoxic testing can determine whether the cytotoxic effects caused are cytostatic (stopping cell growth or division) or cytocidal (killing cells) 12 13 14 The obtained protein is then studied for interaction with active compounds like ligands to form complex compounds using molecular docking. Molecular docking of complex compounds with a network pharmacology approach is a rational step to study the mechanism of compounds against protein targets in disease pathways in cancer by evaluating interaction methods, ligand orientation to the active site of the target protein, and ligand-target protein binding affinity 11 15 Materials and methods Materials The 16-hydroxy-7α-acetoxyroyleanone ( syn. O C. amboinicus 2 Extraction, separation, and purification of extract leaves Briefly, the sample of C. amboinicus n n n 2 f 1 13 In vitro cytotoxicity testing of cancer cells The cancer cells used were MCF-7, A549, HeLa, and Du145, as well as normal cells (CV-1) obtained and studied at the Integrated Laboratory of Universitas Padjadjaran, Bandung, Indonesia. The media were prepared and cultured using RPMI and DMEM-H fluids containing 10% PBS and 50 µg/mL antibiotics. Cell cultures were incubated at 37 °C in 5% CO 2 6 Network pharmacological study SMILE data from the 16-hydroxy-7α-acetoxyroyleanone compound were uploaded to the SWISS target prediction database site ( http://www.swisstargetprediction.ch/ https://www.genecards.org/ https://db.idrblab.net/ttd/ https://www.omim.org/ https://www.disgenet.org/ https://www.biotools.fr/misc/venny 5 7 16 Potential genes between compounds and each selected therapeutic cancer disease were uploaded, constructed, and analyzed using the STRING database ( https://string-db.org/ https://bioinformatics.sdstate.edu/go/ 17 18 Molecular docking The analysis of interactions between the isolates (ligands) and main proteins in the network of cancer pharmacology pathways (receptors) aims to explore intermolecular interactions, affinity, and predictions of the types of bonds that occur theoretically. The isolate structure was optimized for energy using GaussView 5.0 with ground state method settings, DFT, B3LYP, and basis set 3-21G 5 http://www.rcsb.org/ 19 7 Statistical analysis Cytotoxic activity data are reported as mean ± standard error (SEM) with three repetitions. Differences in cytotoxic test data were evaluated statistically using one-way analysis of variance (ANOVA), followed by Tukey’s post hoc multiple comparison test (cytotoxic activity between cells) using GraphPad Prisma 10.01 software. The statistical significance level was set at a p p p p p p Results Structures eludication of compounds 16-hydroxy-7α-acetoxyroyleanone; syn O 1 22 28 6 (MeOH) max m/z 1 tt tt t J tt widened d widened d J d J 13 3 Fig. 1 The 2D and 3D structures of 16-hidroxy-7α-acetoxyroyleanone ( syn O Cytotoxicity testing using the MMT assay The cytotoxicity of the compound 16-hydroxy-7α-acetoxyroyleanone ( syn O 2 2 50 2 2 50 2 1 Fig. 2 Cytotoxic evaluation of the 16-hydroxy-7α-acetoxyroyleanone compound by the MTT test method: ( a b 50 c 50 d p p p p p Table 1 ADMET profile prediction of 16-hydroxy-7α-acetoxyroyleanone compound. No. Parameters ADMET data source pkCSM SwissADME ADMETLab3.0 1. MW (g/mol) 390.476 390.47 390.20 2. Log P 3.043 2.780 2.305 3. H-bond acceptor 6 6 6 4. H-bond donors 2 2 2 5. Rotatable bond 3 4 4 6. TPSA (Å 2 165.193 100.90 100.90 7. GI absorption 73.667% High 77.8% 8. BBB permeant − 0.141 No No 9. P-gp substrate Yes Yes NA 10. CYP1A2 inhibitor No No No 11. CYP2C19 inhibitor No No No 12. CYP2C9 inhibitor No No No 13. CYP2D6 inhibitor No No No 14. CYP3A4 inhibitor No No No 15. % Intestinal absorption 84.209 NA NA 16. Ames’s toxicity No NA 0.442 17. Hepatotoxicity No No NA 18. Max. tolerated dose (mg/kg/day) − 0.089 NA NA 19. Drug likeness NA Yes NA 20. Oral bioavailability NA 0.560 NA Network pharmacological study to obtain the main target protein The gene of the 16-hydroxy-7α-acetoxyroyleanone as the active compound was obtained using the SwissTargetPrediction database, and 50 genes were obtained. Information on target cancer disease genes was obtained using the GeneCards, TTD, OMIM, and DisGeNET databases. Breast cancer disease obtained 14,557 genes, 5750 non-small cell lung cancer (NSCLC) genes, 9184 cervical cancer genes, and 11,420 prostate cancer genes. The gene of the 16-hydroxy-7α-acetoxyroyleanone compound was integrated with the genes of each cancer disease separately using a Venn diagram to obtain target genes between the active compound and cancer disease (Table 2 3 Table 2 Integration of the 16-hydroxy-7α-acetoxyroyleanone compound gene into the respective genes for cancer disease therapy. No. Target cancer type Genes Total 1. Breast cancer OPRD1, FABP4, FABP3, FABP5, OPRM1, AMPD3, PABPC1, ITGAL, PIM1, ACE, ECE1, AGTR1, CCR1, MME, MMP13, MMP1, ADAMTS5, MMP14, HAO2, PPARG, PTGER4, IDO1, HCAR2, CCKBR, GPR35, CYP26A1, GSTM1, KIF11, PTGER2, PTPN1, BCL2L2, BCL2, BCL2A1, BRD4, THRA, THRB, AMPD2, PPARA, EDNRB, GRIN1, CTSA, LTB4R, PSMB5, AVPR2, AVPR1A, ITGA4, ITGB1, OXTR, PCSK7, MMP2 50 2. Non-small cell lung cancer (NSCLC) FABP4, FABP3, FABP5, OPRM1, PABPC1, ITGAL, PIM1, ACE, ECE1, AGTR1, CCR1, MME, MMP13, MMP1, ADAMTS5, MMP14, PPARG, PTGER4, IDO1, CCKBR, GSTM1, KIF11, PTGER2, PTPN1, BCL2L2, BCL2, BCL2A1, BRD4, THRA, THRB, PPARA, EDNRB, GRIN1, PSMB5, AVPR2, ITGB1, MMP2 37 3. Cervical cancer OPRD1, FABP4, FABP3, FABP5, OPRM1, PABPC1, ITGAL, ACE, ECE1, AGTR1, CCR1, MME, MMP13, MMP1, ADAMTS5, MMP14, PPARG, PTGER4, IDO1, GPR35, CYP26A1, GSTM1, KIF11, PTGER2, PTPN1, BCL2L2, BCL2, BCL2A1, BRD4, THRA, THRB, PPARA, EDNRB, GRIN1, CTSA, LTB4R, PSMB5, ITGA4, ITGB1, OXTR, MMP2 41 4. Prostate cancer FABP4, FABP3, FABP5, OPRM1, PABPC1, ITGAL, PIM1, ACE, ECE1, AGTR1, CCR1, MME, MMP13, MMP1, ADAMTS5, MMP14, PPARG, PTGER4, IDO1, CCKBR, CYP26A1, GSTM1, KIF11, PTGER2, PTPN1, BCL2L2, BCL2, BCL2A1, BRD4, THRA, THRB, PPARA, EDNRB, GRIN1, CTSA, PSMB5, AVPR2, AVPR1A, ITGA4, ITGB1, OXTR, PCSK7, MMP2 43 Fig. 3 Network pharmacological study of the 16-hydroxy-7α-acetoxyroyleanone compound against various cancer diseases: ( a b Gene ontology (GO) functional enrichment pathway analysis based on GO biological process, GO cellular component, and GO molecular function classifications. GO and KEGG classifications used an FDR cutoff of 0.05. The results of GO and KEGG enrichment analysis for the top 10 signaling pathways in the enrichment function bubble diagram for each target cancer are shown in Fig. 4 3 Fig. 4 GO analysis of enrichment functions of biological processes (BP), cellular components (CC), molecular functions (MF), and Kyoto Encyclopedia of Genes and Genomes (KEGG) for each target cancer: ( a b c d Table 3 Top 10 enrichment analyses for GO and KEGG of each target cancer. Target cancer Category Term Name Count Pathway genes Enrichment FDR Fold enrichment Breast cancer BP GO:0001990 Reg. of systemic arterial blood pressure by hormone 7 40 1.66E−09 77.00337 BP GO:0003044 Reg. of systemic arterial blood pressure mediated by a chemical signal 7 51 5.97E−09 60.3948 BP GO:0050886 Endocrine proc 9 93 4.39E−10 42.58251 BP GO:0042310 Vasoconstriction 8 83 4.22E−09 42.41149 BP GO:0007204 Positive reg. of cytosolic calcium ion concentration 12 342 4.19E−09 15.43927 BP GO:0044057 Reg. of system proc 17 584 8.53E−12 12.80878 BP GO:0042592 Homeostatic proc 23 1916 1.86E−09 5.282068 BP GO:0051239 Reg. of multicellular organismal proc 28 3024 1.66E−09 4.074252 BP GO:0010033 Response to organic substance 30 3269 3.79E−10 4.038109 BP GO:0065008 Reg. of biological quality 35 4103 8.53E−12 3.753515 CC GO:0034668 Integrin alpha4-beta1 complex 2 3 0.001002 293.3462 CC GO:0097444 Spine apparatus 2 3 0.001002 293.3462 CC GO:0097136 Bcl-2 family protein complex 2 10 0.009027 88.00385 CC GO:0008305 Integrin complex 3 31 0.002512 42.58251 CC GO:0098636 Protein complex involved in cell adhesion 3 53 0.009027 24.90675 CC GO:0009897 External side of plasma membrane 6 459 0.016799 5.751885 CC GO:0005925 Focal adhesion 6 475 0.016799 5.558138 CC GO:0098552 Side of membrane 8 757 0.009472 4.650137 CC GO:0005887 Integral component of plasma membrane 19 1894 3.55E−06 4.414132 CC GO:0031226 Intrinsic component of plasma membrane 19 1978 3.58E−06 4.226676 MF GO:0004953 Icosanoid receptor activity 5 17 1.62E−08 129.4174 MF GO:0008528 G protein-coupled peptide receptor activity 12 156 2.74E−13 33.84763 MF GO:0042562 Hormone binding 7 93 5.42E−08 33.11973 MF GO:0001653 Peptide receptor activity 12 162 2.74E−13 32.59402 MF GO:0004222 Metalloendopeptidase activity 8 126 1.91E−08 27.93773 MF GO:0042277 Peptide binding 12 402 5.20E−09 13.1349 MF GO:0033218 Amide binding 12 481 2.25E−08 10.97761 MF GO:0004930 G protein-coupled receptor activity 16 1029 2.25E−08 6.841893 MF GO:0038023 Signaling receptor activity 23 1908 3.56E−10 5.304215 MF GO:0060089 Molecular transducer activity 23 1908 3.56E−10 5.304215 KEGG Path:hsa04614 Renin-angiotensin system 4 23 7.93E−06 76.52508 KEGG Path:hsa03320 PPAR signaling pathway 6 75 1.24E−06 35.20154 KEGG Path:hsa04924 Renin secretion 4 69 0.000478 25.50836 KEGG Path:hsa04080 Neuroactive ligand-receptor interaction 15 362 3.00E−13 18.23284 KEGG Path:hsa04933 AGE-RAGE signaling pathway in diabetic complications 4 100 0.001764 17.60077 KEGG Path:hsa04670 Leukocyte transendothelial migration 4 114 0.002501 15.43927 KEGG Path:hsa04926 Relaxin signaling pathway 4 129 0.003302 13.64401 KEGG Path:hsa04020 Calcium signaling pathway 6 240 0.000478 11.00048 KEGG Path:hsa04024 cAMP signaling pathway 5 221 0.002501 9.955186 KEGG Path:hsa05200 Pathways in cancer 11 530 1.24E−06 9.132475 NSCLC BP GO:0044057 Reg. of system proc 13 584 7.41E−09 13.40361 BP GO:0006954 Inflammatory response 14 892 3.15E−08 9.450496 BP GO:0009725 Response to hormone 14 898 3.15E−08 9.387352 BP GO:0048878 Chemical homeostasis 15 1241 1.14E−07 7.27798 BP GO:0009719 Response to endogenous stimulus 17 1660 8.26E−08 6.166408 BP GO:0042592 Homeostatic proc 18 1916 8.26E−08 5.656768 BP GO:0051239 Reg. of multicellular organismal proc 23 3024 7.41E−09 4.579704 BP GO:0010033 Response to organic substance 24 3269 7.41E−09 4.420666 BP GO:0065008 Reg. of biological quality 26 4103 7.41E−09 3.815603 BP GO:0042221 Response to chemical 26 4821 1.14E−07 3.247339 z GO:0097136 Bcl-2 family protein complex 2 10 0.009308 120.4263 CC GO:0008305 Integrin complex 2 31 0.021713 38.8472 CC GO:0005741 Mitochondrial outer membrane 4 222 0.021713 10.84922 CC GO:0009897 External side of plasma membrane 5 459 0.021713 6.559168 CC GO:0005925 Focal adhesion 5 475 0.021713 6.338227 CC GO:0005768 Endosome 8 1232 0.021713 3.909945 CC GO:0005887 Integral component of plasma membrane 12 1894 0.0063 3.814984 CC GO:0031226 Intrinsic component of plasma membrane 12 1978 0.0063 3.652972 CC GO:0005615 Extracellular space 14 3577 0.021713 2.356679 CC GO:0005576 Extracellular region 17 4673 0.021713 2.190506 MF GO:0004222 Metalloendopeptidase activity 8 126 8.60E−09 38.23058 MF GO:0008237 Metallopeptidase activity 8 204 1.99E−07 23.613 MF GO:0008528 G protein-coupled peptide receptor activity 6 156 6.29E−06 23.15891 MF GO:0042277 Peptide binding 9 402 9.06E−07 13.48056 MF GO:0033218 Amide binding 9 481 3.52E−06 11.2665 MF GO:0004175 Endopeptidase activity 9 497 3.98E−06 10.90379 MF GO:0008270 Zinc ion binding 13 947 1.99E−07 8.265798 MF GO:0046914 Transition metal ion binding 14 1247 4.00E−07 6.760098 MF GO:0038023 Signaling receptor activity 15 1908 5.03E−06 4.733739 MF GO:0060089 Molecular transducer activity 15 1908 5.03E−06 4.733739 KEGG Path:hsa04614 Renin-angiotensin system 3 23 0.000215 78.5389 KEGG Path:hsa03320 PPAR signaling pathway 6 75 1.26E−07 48.17053 KEGG Path:hsa04924 Renin secretion 4 69 0.00019 34.90618 KEGG Path:hsa04933 AGE-RAGE signaling pathway in diabetic complications 4 100 0.000554 24.08526 KEGG Path:hsa04926 Relaxin signaling pathway 4 129 0.001288 18.67075 KEGG Path:hsa04928 Parathyroid hormone synthesis secretion and action 3 106 0.010651 17.04146 KEGG Path:hsa04080 Neuroactive ligand-receptor interaction 10 362 4.07E−08 16.63347 KEGG Path:hsa05200 Pathways in cancer 11 530 4.67E−08 12.49707 KEGG Path:hsa05415 Diabetic cardiomyopathy 4 203 0.006442 11.86466 KEGG Path:hsa04020 Calcium signaling pathway 4 240 0.010651 10.03553 Cervical cancer BP GO:0044057 Reg. of system proc 15 584 2.18E−10 13.66737 BP GO:0007610 Behavior 13 659 3.60E−08 10.49698 BP GO:0006954 Inflammatory response 16 892 2.14E−09 9.544687 BP GO:0009725 Response to hormone 15 898 1.45E−08 8.888357 BP GO:0009719 Response to endogenous stimulus 19 1660 1.31E−08 6.090488 BP GO:0010033 Response to organic substance 27 3269 4.59E−10 4.394965 BP GO:0051239 Reg. of multicellular organismal proc 24 3024 1.51E−08 4.223145 BP GO:0065008 Reg. of biological quality 28 4103 5.47E−09 3.631308 BP GO:0006950 Response to stress 29 4424 5.40E−09 3.488104 BP GO:0042221 Response to chemical 29 4821 2.18E−08 3.200865 CC GO:0034668 Integrin alpha4-beta1 complex 2 3 0.000641 354.7442 CC GO:0097444 Spine apparatus 2 3 0.000641 354.7442 CC GO:0097136 Bcl-2 family protein complex 2 10 0.004767 106.4233 CC GO:0008305 Integrin complex 3 31 0.001329 51.49512 CC GO:0098636 Protein complex involved in cell adhesion 3 53 0.004767 30.11979 CC GO:0009897 External side of plasma membrane 6 459 0.005648 6.955768 CC GO:0005925 Focal adhesion 6 475 0.006113 6.721469 CC GO:0098552 Side of membrane 8 757 0.00297 5.623422 CC GO:0005887 Integral component of plasma membrane 17 1894 4.62E−06 4.776123 CC GO:0031226 Intrinsic component of plasma membrane 17 1978 4.62E−06 4.573295 MF GO:0004953 Icosanoid receptor activity 5 17 8.52E−09 156.5048 MF GO:0004222 Metalloendopeptidase activity 8 126 8.44E−09 33.78516 MF GO:0008528 G protein-coupled peptide receptor activity 9 156 2.49E−09 30.69902 MF GO:0001653 Peptide receptor activity 9 162 2.49E−09 29.56202 MF GO:0008237 Metallopeptidase activity 8 204 1.68E−07 20.86731 MF GO:0042277 Peptide binding 9 402 1.47E−06 11.91305 MF GO:0008270 Zinc ion binding 13 947 4.22E−07 7.304659 MF GO:0046914 Transition metal ion binding 14 1247 1.13E−06 5.97404 MF GO:0038023 Signaling receptor activity 19 1908 1.67E−08 5.298852 MF GO:0060089 Molecular transducer activity 19 1908 1.67E−08 5.298852 KEGG Path:hsa04614 Renin-angiotensin system 4 23 3.47E−06 92.54196 KEGG Path:hsa03320 PPAR signaling pathway 6 75 4.17E−07 42.5693 KEGG Path:hsa04924 Renin secretion 4 69 0.000255 30.84732 KEGG Path:hsa04670 Leukocyte transendothelial migration 4 114 0.001542 18.67075 KEGG Path:hsa05410 Hypertrophic cardiomyopathy 3 90 0.010729 17.73721 KEGG Path:hsa04080 Neuroactive ligand-receptor interaction 12 362 3.02E−10 17.63921 KEGG Path:hsa04926 Relaxin signaling pathway 4 129 0.002136 16.49973 KEGG Path:hsa05415 Diabetic cardiomyopathy 4 203 0.010545 10.48505 KEGG Path:hsa05200 Pathways in cancer 10 530 1.96E−06 10.03993 KEGG Path:hsa04024 cAMP signaling pathway 4 221 0.011592 9.631064 Prostate cancer BP GO:0001990 Reg. of systemic arterial blood pressure by hormone 7 40 6.92E−10 91.003977 BP GO:0003044 Reg. of systemic arterial blood pressure mediated by a chemical signal 7 51 2.12E−09 71.375668 BP GO:0042310 Vasoconstriction 8 83 1.79E−09 50.122673 BP GO:0050886 Endocrine proc 8 93 2.53E−09 44.733138 BP GO:0044057 Reg. of system proc 15 584 1.09E−10 13.356748 BP GO:0009725 Response to hormone 16 898 1.79E−09 9.265438 BP GO:0009719 Response to endogenous stimulus 20 1660 1.79E−09 6.265334 BP GO:0010033 Response to organic substance 28 3269 1.03E−10 4.454156 BP GO:0051239 Reg. of multicellular organismal proc 25 3024 2.82E−09 4.299130 BP GO:0065008 Reg. of biological quality 31 4103 7.77E−11 3.929004 CC GO:0034668 Integrin alpha4-beta1 complex 2 3 0.000884 346.681818 CC GO:0097136 Bcl-2 family protein complex 2 10 0.005637 104.004546 CC GO:0008305 Integrin complex 3 31 0.001759 50.324780 CC GO:0098636 Protein complex involved in cell adhesion 3 53 0.005637 29.435249 CC GO:0009897 External side of plasma membrane 6 459 0.007147 6.797683 CC GO:0005925 Focal adhesion 6 475 0.007597 6.568708 CC GO:0030055 Cell-substrate junction 6 484 0.007597 6.446563 CC GO:0098552 Side of membrane 8 757 0.00418 5.495617 CC GO:0005887 Integral component of plasma membrane 15 1894 0.000268 4.118448 CC GO:0031226 Intrinsic component of plasma membrane 15 1978 0.000268 3.943549 MF GO:0042562 Hormone binding 7 93 4.35E−08 39.141500 MF GO:0004222 Metalloendopeptidase activity 8 126 3.04E−08 33.017320 MF GO:0008528 G protein-coupled peptide receptor activity 8 156 4.35E−08 26.667830 MF GO:0001653 Peptide receptor activity 8 162 4.70E−08 25.680130 MF GO:0008237 Metallopeptidase activity 8 204 1.61E−07 20.393050 MF GO:0042277 Peptide binding 11 402 3.04E−08 14.229480 MF GO:0033218 Amide binding 11 481 6.70E−08 11.892410 MF GO:0046914 Transition metal ion binding 15 1247 1.63E−07 6.255285 MF GO:0038023 Signaling receptor activity 18 1908 1.61E−07 4.905875 MF GO:0060089 Molecular transducer activity 18 1908 1.61E−07 4.905875 KEGG Path:hsa04614 Renin-angiotensin system 4 23 3.87E−06 90.438740 KEGG Path:hsa03320 PPAR signaling pathway 6 75 3.26E−07 41.601820 KEGG Path:hsa04924 Renin secretion 4 69 0.000236 30.146250 KEGG Path:hsa04933 AGE-RAGE signaling pathway in diabetic complications 4 100 0.000879 20.800910 KEGG Path:hsa04670 Leukocyte transendothelial migration 4 114 0.001284 18.246410 KEGG Path:hsa04080 Neuroactive ligand-receptor interaction 12 362 4.14E−10 17.238320 KEGG Path:hsa04926 Relaxin signaling pathway 4 129 0.001844 16.124740 KEGG Path:hsa04020 Calcium signaling pathway 6 240 0.000191 13.000570 KEGG Path:hsa05200 Pathways in cancer 11 530 2.69E−07 10.792920 KEGG Path:hsa05415 Diabetic cardiomyopathy 4 203 0.009339 10.246750 The determination of the main protein for each cancer disease are focused on the pathways in cancer from the results of KEGG enrichment analysis. Proteins involved in the pathways in cancer for the active compounds of all cancer disease targets provide the same protein, namely 10 proteins (AGTR1, EDNRB, GSTM1, ITGB1, MMP2, PPARG, PTGER2, PTGER4, and BCL2), as shown in Table S2. The acquisition of the main protein target in the cancer pathway is determined by three proteins shown in Fig. 5 Fig. 5 An enrichment analysis of the determination of the main target proteins based on KEGG in cancer pathways; ( a b Molecular docking study A molecular docking study was conducted on the top three target genes obtained from the results of network pharmacological studies focused on pharmacological pathways (pathways in cancer). The top three genes that are proteins in each cancer are matrix metalloproteinase-2 (MMP2), peroxisome proliferator-activated receptor gamma (PPARG), and B-cell lymphoma 2 (BCl2). The energy optimization results of the 16-hydroxy-7α-acetoxyroyleanone compound are − 1300.609 kJ/mol with a dipole moment of 3.4830 Debye 5 4 6 Table 4 The PDB ID of the protein receptor and the RMSD value of the native ligand for each protein target. No. Target cancers MMP2 PPARG BCL2 PDB ID RMSD (Å) PDB ID RMSD (Å) PDB ID RMSD (Å) 1. Breast cancer 3AYU 20 0.38 4Y29 21 0.62 4MAN 22 1.76 2. NSCLC 7XJO 23 0.43 6DGL 24 0.41 6GL8 25 0.68 3. Cervical cancer 1HOV 26 1.16 6C5T 27 0.96 4AQ3 28 0.90 4. Prostate cancer 7XGJ 29 1.05 2HFP 30 0.37 2W3L 31 0.48 Fig. 6 Molecular study of the 16-hydroxy-7α-acetoxyroyleanone compound against the main target protein for cancer therapy. Discussion Given the absence of reports on the exploration of the compound 16-hydroxy-7α-acetoxyroyleanone ( syn O Coleus amboinicus 2 5 32 33 33 34 The results of the cytotoxic activity test (IC 50 50 2 35 36 37 38 2 39 6 7 The ADMET prediction study provides balanced information between potential drug activity and appropriate selectivity in the selection and clinical development of potential new drug candidates 40 41 1 Network pharmacology studies play an important role in systematic and comprehensive investigations that highlight various active ingredients, techniques/tools/databases related to drug discovery, and development for various diseases. Network pharmacology is a common approach used in the era of modern drug discovery 42 43 44 MMP2 belongs to a family of zinc and calcium-containing enzymes in the degradation and remodeling of the extracellular matrix (ECM). Under normal conditions, MMP2 plays an important role together with MMP9 in ECM remodeling, while in cancer conditions, MMP2 promotes invasion and metastasis by facilitating the vascular endothelial growth factor (VEGF) pathway 45 20 46 47 48 Peroxisome proliferator-activated receptor gamma (PPARG) in normal conditions functions as a transcription factor that regulates gene expression after ligand activation, increases fatty acid absorption, increases triglyceride formation, regulates insulin sensitivity in glucose metabolism, and regulates genes encoding proteins controlling metabolic homeostasis in various organs 49 50 24 51 B-cell lymphoma 2 (BCl2) in the body functions to regulate the complex interactions between pro-apoptotic, pro-survival, and anti-apoptotic members and balances the decision between cell life and death. BCl2 protein also functions to regulate the intrinsic pathway and prevent the release of cytochrome C from mitochondria 52 53 54 55 Conclusion The isolated 16-hydroxy-7α-acetoxyroyleanone, syn. O 50 50 Supplementary Information Below is the link to the electronic supplementary material.  Supplementary Material 1  Supplementary Material 2  Supplementary Material 3  Supplementary Material 4 Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Acknowledgements The authors are grateful for financial support provided by the (1) Indonesian Education Scholarship (BPI), (2) Center for Higher Education Funding and Assessment Ministry of Higher Education, Science, and Technology of Republic Indonesia, and (3) Indonesia Endowment Fund for Education (LPPD) to the author on behalf of Kasta Gurning (BPI Decree Number 02380/BPPT/BPI.06/9/2024), Friska Septiani Silitonga (BPI Decree Number 02111/J5.2.3./BPI.06/9/2022), and Yehezkiel Steven Kurniawan, are greatly appreciated. We deeply appreciate all the members of our team. Author contributions K.G. and Y.S.K. performed the experiments, collected data, interpreted and analyzed the data, wrote and prepared the original draft, revised, and edited the manuscript; F.S.S. performed experiments and collected data; G.P. helped with curation, formal analysis, and investigation; E.A. supervision, validation, and writing—review and editing; W.H. funding acquisition, validation, and writing—review and editing. All authors have read, reviewed, and approved of the final version of the article. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Data availability Data are provided within the manuscript or supplementary information files. The datasets used and/or analyzed during the current study are included in this published article and its supplementary information files. Correspondence and requests for materials should be addressed to Kasta Gurning or Winarto Haryadi. Declarations Competing interests The authors declare no competing interests. References 1. Ślusarczyk S Phytochemical profile and antioxidant activities of Coleus amboinicus Molecules 2021 26 2915 10.3390/molecules26102915 34068950 PMC8156032 Ślusarczyk, S. et al. Phytochemical profile and antioxidant activities of Coleus amboinicus Molecules 26 34068950 10.3390/molecules26102915 PMC8156032 2. Gurning K Haryadi W Sastrohamidjojo H Isolation and characterization of antioxidant compounds of bangun-bangun ( Coleus amboinicus Rasayan J. Chem. 2021 14 248 253 10.31788/rjc.2021.1416077 Gurning, K., Haryadi, W. & Sastrohamidjojo, H. Isolation and characterization of antioxidant compounds of bangun-bangun ( Coleus amboinicus Rasayan J. Chem. 14 3. Paul K Traditional uses, phytochemistry, and pharmacological activities of Coleus amboinicus Curr. Pharm. Des. 2024 30 519 535 10.2174/0113816128283267240130062600 38321896 Paul, K. et al. Traditional uses, phytochemistry, and pharmacological activities of Coleus amboinicus Curr. Pharm. Des. 30 38321896 10.2174/0113816128283267240130062600 4. Gurning K Haryadi W Potential antioxidants of secondary metabolite isolates ethyl acetate fraction Coleus amboinicus ScienceRise Pharm. Sci. 2022 10.15587/2519-4852.2022.266401 Gurning, K. & Haryadi, W. Potential antioxidants of secondary metabolite isolates ethyl acetate fraction Coleus amboinicus ScienceRise Pharm. Sci. 5. Haryadi W Gurning K Astuti E Molecular target identification of two Coleus amboinicus J. Appl. Pharm. Sci. 2024 14 203 210 10.7324/JAPS.2024.164753 Haryadi, W., Gurning, K. & Astuti, E. Molecular target identification of two Coleus amboinicus J. Appl. Pharm. Sci. 14 6. Gurning K Suratno S Astuti E Haryadi W Untargeted LC/HRMS metabolomics analysis and anticancer activity assay on MCF-7 and A549 cells from Coleus amboinicus IJ. Pharm. Res. 2024 23 e143494 10.5812/ijpr-143494 PMC11302430 39108647 Gurning, K., Suratno, S., Astuti, E. & Haryadi, W. Untargeted LC/HRMS metabolomics analysis and anticancer activity assay on MCF-7 and A549 cells from Coleus amboinicus IJ. Pharm. Res. 23 10.5812/ijpr-143494 PMC11302430 39108647 7. Haryadi W Gurning K Fachiroh J Astuti E Potential of bioactive compounds in Coleus amboinicus J. Multidiscip. Appl. Nat. Sci. 2025 5 267 287 10.47352/jmans.2774-3047.246 Haryadi, W., Gurning, K., Fachiroh, J. & Astuti, E. Potential of bioactive compounds in Coleus amboinicus J. Multidiscip. Appl. Nat. Sci. 5 8. Fronza M Abietane diterpenes induce cytotoxic effects in human pancreatic cancer cell line MIA PaCa-2 through different modes of action Phytochemistry 2012 78 107 119 10.1016/j.phytochem.2012.02.015 22436445 Fronza, M. et al. Abietane diterpenes induce cytotoxic effects in human pancreatic cancer cell line MIA PaCa-2 through different modes of action. Phytochemistry 78 22436445 10.1016/j.phytochem.2012.02.015 9. Fronza M In vitro cytotoxic activity of abietane diterpenes from peltodon longipes as well as Salvia miltiorrhiza Salvia sahendica Bioorg. Med. Chem. 2011 19 4876 4881 10.1016/j.bmc.2011.06.067 21775156 Fronza, M. et al. In vitro cytotoxic activity of abietane diterpenes from peltodon longipes as well as Salvia miltiorrhiza Salvia sahendica Bioorg. Med. Chem. 19 21775156 10.1016/j.bmc.2011.06.067 10. Gáborová M Šmejkal K Kubínová R Abietane diterpenes of the genus plectranthus sensu lato Molecules 2022 27 166 10.3390/molecules27010166 PMC8746610 35011401 Gáborová, M., Šmejkal, K. & Kubínová, R. Abietane diterpenes of the genus plectranthus sensu lato. Molecules 27 10.3390/molecules27010166 PMC8746610 35011401 11. Mirzaei HH Firuzi O Jassbi AR Diterpenoids from roots of Salvia lachnocalyx Iran. J. Pharm. Res. 2020 19 85 10.22037/ijpr.2019.15429.13095 33841524 PMC8019878 Mirzaei, H. H., Firuzi, O. & Jassbi, A. R. Diterpenoids from roots of Salvia lachnocalyx Iran. J. Pharm. Res. 19 33841524 10.22037/ijpr.2019.15429.13095 PMC8019878 12. Houghton P The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity Methods 2007 42 377 387 10.1016/j.ymeth.2007.01.003 17560325 Houghton, P. et al. The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity. Methods 42 17560325 10.1016/j.ymeth.2007.01.003 13. Cai L Comparison of cytotoxicity evaluation of anticancer drugs between real-time cell analysis and CCK-8 method ACS Omega 2019 4 12036 12042 10.1021/acsomega.9b01142 31460316 PMC6682106 Cai, L. et al. Comparison of cytotoxicity evaluation of anticancer drugs between real-time cell analysis and CCK-8 method. ACS Omega 4 31460316 10.1021/acsomega.9b01142 PMC6682106 14. Federico A Integrated network pharmacology approach for drug combination discovery: A multi-cancer case study Cancers 2022 14 2043 10.3390/cancers14082043 35454948 PMC9028433 Federico, A. et al. Integrated network pharmacology approach for drug combination discovery: A multi-cancer case study. Cancers 14 35454948 10.3390/cancers14082043 PMC9028433 15. Pinzi L Rastelli G Molecular docking: Shifting paradigms in drug discovery Int. J. Mol. Sci. 2019 20 4331 10.3390/ijms20184331 31487867 PMC6769923 Pinzi, L. & Rastelli, G. Molecular docking: Shifting paradigms in drug discovery. Int. J. Mol. Sci. 20 31487867 10.3390/ijms20184331 PMC6769923 16. Basar MA Identification of drug and protein-protein interaction network among stress and depression: A bioinformatics approach Inform. Med. Unlocked 2023 37 101174 10.1016/j.imu.2023.101174 Basar, M. A. et al. Identification of drug and protein-protein interaction network among stress and depression: A bioinformatics approach. Inform. Med. Unlocked 37 17. Kanehisa M Goto S KEGG: Kyoto encyclopedia of genes and genomes Nucleic Acids Res. 2000 28 27 30 10.1016/j.imu.2023.101174 10592173 PMC102409 Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28 10592173 10.1093/nar/28.1.27 PMC102409 18. Kanehisa M Furumichi M Sato Y Kawashima M Ishiguro-Watanabe M KEGG for taxonomy-based analysis of pathways and genomes Nucleic Acids Res. 2023 51 D587 D592 10.1093/nar/gkac963 36300620 PMC9825424 Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51 36300620 10.1093/nar/gkac963 PMC9825424 19. Gurning K Primahana G Astuti E Haryadi W In vitro cytotoxic and molecular docking studies of the network pharmacology approach from bioactive compounds of Coleus amboinicus Adv. Pharmacol. Pharm. Sci. 2025 2025 5946648 10.1155/adpp/5946648 40687624 PMC12274097 Gurning, K., Primahana, G., Astuti, E. & Haryadi, W. In vitro cytotoxic and molecular docking studies of the network pharmacology approach from bioactive compounds of Coleus amboinicus Adv. Pharmacol. Pharm. Sci. 2025 40687624 10.1155/adpp/5946648 PMC12274097 20. Proença S Pyridine-containing macrocycles display MMP-2/9 inhibitory activity and distinct effects on migration and invasion of 2D and 3D breast cancer models Int. J. Mol. Sci. 2019 20 5109 10.3390/ijms20205109 31618886 PMC6829403 Proença, S. et al. Pyridine-containing macrocycles display MMP-2/9 inhibitory activity and distinct effects on migration and invasion of 2D and 3D breast cancer models. Int. J. Mol. Sci. 20 31618886 10.3390/ijms20205109 PMC6829403 21. Vyas B Kumar S Bhowmik R Akhter M Predicting the molecular mechanism-driven progression of breast cancer through comprehensive network pharmacology and molecular docking approach Sci. Rep. 2023 13 13729 10.1038/s41598-023-40684-7 37607964 PMC10444824 Vyas, B., Kumar, S., Bhowmik, R. & Akhter, M. Predicting the molecular mechanism-driven progression of breast cancer through comprehensive network pharmacology and molecular docking approach. Sci. Rep. 13 37607964 10.1038/s41598-023-40684-7 PMC10444824 22. Othman B Comprehensive pharmacokinetic profiling and molecular docking analysis of natural bioactive compounds targeting oncogenic biomarkers in breast cancer Sci. Rep. 2025 15 1 19 10.1038/s41598-024-84401-4 39948091 PMC11825887 Othman, B. et al. Comprehensive pharmacokinetic profiling and molecular docking analysis of natural bioactive compounds targeting oncogenic biomarkers in breast cancer. Sci. Rep. 15 39948091 10.1038/s41598-024-84401-4 PMC11825887 23. Ahmad A Molecular docking and inhibition of matrix metalloproteinase-2 by novel difluorinatedbenzylidene curcumin analog Am. J. Transl. Res. 2015 7 298 308 25901198 PMC4399093 Ahmad, A. et al. Molecular docking and inhibition of matrix metalloproteinase-2 by novel difluorinatedbenzylidene curcumin analog. Am. J. Transl. Res. 7 25901198 PMC4399093 24. Zhang J Tang M Shang J PPARγ modulators in lung cancer: Molecular mechanisms, clinical prospects, and challenges Biomolecules 2024 14 190 10.3390/biom14020190 38397426 PMC10886696 Zhang, J., Tang, M. & Shang, J. PPARγ modulators in lung cancer: Molecular mechanisms, clinical prospects, and challenges. Biomolecules 14 38397426 10.3390/biom14020190 PMC10886696 25. Mongre RK Novel carbazole-piperazine hybrid small molecule induces apoptosis by targeting BCL-2 and inhibits tumor progression in lung adenocarcinoma in vitro and xenograft mice model Cancers 2019 11 1245 10.3390/cancers11091245 31450709 PMC6770606 Mongre, R. K. et al. Novel carbazole-piperazine hybrid small molecule induces apoptosis by targeting BCL-2 and inhibits tumor progression in lung adenocarcinoma in vitro and xenograft mice model. Cancers 11 31450709 10.3390/cancers11091245 PMC6770606 26. Sidhu H Gautam LK Capalash N Unraveling the molecular mechanism of l-menthol against cervical cancer based on network pharmacology, molecular docking and in vitro analysis Mol. Divers 2023 27 323 340 10.1007/s11030-022-10429-1 35467269 Sidhu, H., Gautam, L. K. & Capalash, N. Unraveling the molecular mechanism of l-menthol against cervical cancer based on network pharmacology, molecular docking and in vitro analysis. Mol. Divers 27 35467269 10.1007/s11030-022-10429-1 27. Sivamani Y A promising in silico protocol to develop novel PPARγ antagonists as potential anticancer agents: Design, synthesis and experimental validation via PPARγ protein activity and competitive binding assay Comput. Biol. Chem. 2021 95 107600 10.1016/j.compbiolchem.2021.107600 34794076 Sivamani, Y. et al. A promising in silico protocol to develop novel PPARγ antagonists as potential anticancer agents: Design, synthesis and experimental validation via PPARγ protein activity and competitive binding assay. Comput. Biol. Chem. 95 34794076 10.1016/j.compbiolchem.2021.107600 28. Aini AQ Supandi S Adelina R Maharani DA The study of molecular docking and molecular dynamics simulation chemical compound of Pycnarrhena cauliflora Indones. J. Cancer Chemoprev. 2024 15 63 75 10.14499/indonesianjcanchemoprev15iss1pp63-75 Aini, A. Q., Supandi, S., Adelina, R. & Maharani, D. A. The study of molecular docking and molecular dynamics simulation chemical compound of Pycnarrhena cauliflora Indones. J. Cancer Chemoprev. 15 29. Shojaei S Zandieh MR Jamshidi S Taherkhani A Azadian Z Exploring cinnamic acids as potent antimetastatic agents for cancer therapy: Molecular docking and dynamic simulation against MMP2 Eur. J. Cancer Care 2024 2024 1 19 10.1155/2024/3727684 Shojaei, S., Zandieh, M. R., Jamshidi, S., Taherkhani, A. & Azadian, Z. Exploring cinnamic acids as potent antimetastatic agents for cancer therapy: Molecular docking and dynamic simulation against MMP2. Eur. J. Cancer Care 2024 30. Almahmoud S Virtual screening and biological evaluation of PPARγ antagonists as potential anti-prostate cancer agents Bioorg. Med. Chem. 2021 46 116368 10.1016/j.bmc.2021.116368 34433102 Almahmoud, S. et al. Virtual screening and biological evaluation of PPARγ antagonists as potential anti-prostate cancer agents. Bioorg. Med. Chem. 46 34433102 10.1016/j.bmc.2021.116368 31. Saffari-Chaleshtori J Heidari-Sureshjani E Moradi F Heidarian E The effects of thymoquinone on viability, and anti-apoptotic factors (BCL-XL, BCL-2, MCL-1) in prostate cancer (PC3) cells: An in vitro and computer-simulated environment study Adv. Pharm. Bull. 2019 9 490 496 10.15171/apb.2019.058 31592099 PMC6773927 Saffari-Chaleshtori, J., Heidari-Sureshjani, E., Moradi, F. & Heidarian, E. The effects of thymoquinone on viability, and anti-apoptotic factors (BCL-XL, BCL-2, MCL-1) in prostate cancer (PC3) cells: An in vitro and computer-simulated environment study. Adv. Pharm. Bull. 9 31592099 10.15171/apb.2019.058 PMC6773927 32. Sung H Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 2021 71 209 249 10.3322/caac.21660 33538338 Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 33538338 10.3322/caac.21660 33. Delam H Moradi Kouchi Z Safari H The effect of herbal medicine in relieving complications related to cancer treatments: An evidence-based systematic review J. Herb. Med. 2024 48 100944 10.1016/j.hermed.2024.100944 Delam, H., Moradi Kouchi, Z. & Safari, H. The effect of herbal medicine in relieving complications related to cancer treatments: An evidence-based systematic review. J. Herb. Med. 48 34. Wei D The mechanism of Wenhua decoction in the treatment of non-small cell lung cancer by network pharmacology and molecular dynamics simulation J. Herb. Med. 2024 48 100934 10.1016/j.hermed.2024.100934 Wei, D. The mechanism of Wenhua decoction in the treatment of non-small cell lung cancer by network pharmacology and molecular dynamics simulation. J. Herb. Med. 48 35. Dahham SS The anticancer, antioxidant and antimicrobial properties of the sesquiterpene β-caryophyllene from the essential oil of Aquilaria crassna Molecules 2015 20 11808 11829 10.3390/molecules200711808 26132906 PMC6331975 Dahham, S. S. et al. The anticancer, antioxidant and antimicrobial properties of the sesquiterpene β-caryophyllene from the essential oil of Aquilaria crassna Molecules 20 26132906 10.3390/molecules200711808 PMC6331975 36. To’bungan N Pratiwi R Widyarini S Nugroho LH Cytotoxicity extract and fraction of knobweed ( Hyptis capitata Biodiversitas 2022 23 572 580 10.13057/biodiv/d230162 To’bungan, N., Pratiwi, R., Widyarini, S. & Nugroho, L. H. Cytotoxicity extract and fraction of knobweed ( Hyptis capitata Biodiversitas 23 37. Laila F Fardiaz D Yuliana ND Damanik MRM Nur Annisa Dewi F Methanol extract of Coleus amboinicus Int. J. Food Sci. 2020 2020 9068326 10.1155/2020/9068326 32047805 PMC7003269 Laila, F., Fardiaz, D., Yuliana, N. D., Damanik, M. R. M. & Nur Annisa Dewi, F. Methanol extract of Coleus amboinicus Int. J. Food Sci. 2020 32047805 10.1155/2020/9068326 PMC7003269 38. Mujamammi AH Phyto-fabrication and characterization of Coleus amboinicus J. Inorg. Organomet. Polym. Mater. 2024 34 2581 2595 10.1007/s10904-024-02997-6 Mujamammi, A. H. et al. Phyto-fabrication and characterization of Coleus amboinicus J. Inorg. Organomet. Polym. Mater. 34 39. Narayanan M Synthesis and characterization of TiO 2 Coleus aromaticus Environ. Res. 2021 200 111335 10.1016/j.envres.2021.111335 34051200 Narayanan, M. et al. Synthesis and characterization of TiO 2 Coleus aromaticus Environ. Res. 200 34051200 10.1016/j.envres.2021.111335 40. Kar S Leszczynski J Open access in silico tools to predict the ADMET profiling of drug candidates Expert Opin. Drug Discov. 2020 15 1473 1487 10.1080/17460441.2020.1798926 32735147 Kar, S. & Leszczynski, J. Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opin. Drug Discov. 15 32735147 10.1080/17460441.2020.1798926 41. Belkadi A Kenouche S Melkemi N Daoud I Djebaili R K-means clustering analysis, ADME/pharmacokinetic prediction, MEP, and molecular docking studies of potential cytotoxic agents Struct. Chemi. 2021 32 6 2235 2249 10.1007/s11224-021-01796-w Belkadi, A., Kenouche, S., Melkemi, N., Daoud, I. & Djebaili, R. K-means clustering analysis, ADME/pharmacokinetic prediction, MEP, and molecular docking studies of potential cytotoxic agents. Struct. Chemi. 32 42. Noor F Network pharmacology approach for medicinal plants: Review and assessment Pharmaceuticals 2022 15 572 10.3390/ph15050572 35631398 PMC9143318 Noor, F. et al. Network pharmacology approach for medicinal plants: Review and assessment. Pharmaceuticals 15 35631398 10.3390/ph15050572 PMC9143318 43. Wang X Wang ZY Zheng JH Li S TCM network pharmacology: A new trend towards combining computational, experimental and clinical approaches Chin. J. Nat. Med. 2021 19 1 11 10.1016/S1875-5364(21)60001-8 33516447 Wang, X., Wang, Z. Y., Zheng, J. H. & Li, S. TCM network pharmacology: A new trend towards combining computational, experimental and clinical approaches. Chin. J. Nat. Med. 19 33516447 10.1016/S1875-5364(21)60001-8 44. Zhou Z Applications of network pharmacology in traditional Chinese medicine research Evid. Based Complement. Altern. Med. 2020 2020 1 7 10.1155/2020/1646905 PMC7042531 32148533 Zhou, Z. et al. Applications of network pharmacology in traditional Chinese medicine research. Evid. Based Complement. Altern. Med. 2020 10.1155/2020/1646905 PMC7042531 32148533 45. Wolosowicz M Prokopiuk S Kaminski TW The complex role of matrix metalloproteinase-2 (MMP-2) in health and disease Int. J. Mol. Sci. 2024 25 13691 10.3390/ijms252413691 39769454 PMC11728377 Wolosowicz, M., Prokopiuk, S. & Kaminski, T. W. The complex role of matrix metalloproteinase-2 (MMP-2) in health and disease. Int. J. Mol. Sci. 25 39769454 10.3390/ijms252413691 PMC11728377 46. Ibraheem Q The role of matrix metalloproteinase-2 (MMP2) in colorectal cancer progression: Correlation with clinicopathological features and impact on cellular processes Cureus 2024 16 e61941 10.7759/cureus.61941 38978899 PMC11229389 Ibraheem, Q. The role of matrix metalloproteinase-2 (MMP2) in colorectal cancer progression: Correlation with clinicopathological features and impact on cellular processes. Cureus 16 38978899 10.7759/cureus.61941 PMC11229389 47. Ma Y Potential binding of cryptotanshinone with hemoglobin and antimetastatic effects against breast cancer cells through alleviating the expression of MMP-2/-9 Arab. J. Chem. 2023 16 105071 10.1016/j.arabjc.2023.105071 Ma, Y. et al. Potential binding of cryptotanshinone with hemoglobin and antimetastatic effects against breast cancer cells through alleviating the expression of MMP-2/-9. Arab. J. Chem. 16 48. Wang Y Using network pharmacology and molecular docking to explore the mechanism of Shan Ci Gu ( Cremastra appendiculata Front. Chem. 2021 9 682862 10.3389/fchem.2021.682862 34178945 PMC8220148 Wang, Y. et al. Using network pharmacology and molecular docking to explore the mechanism of Shan Ci Gu ( Cremastra appendiculata Front. Chem. 9 34178945 10.3389/fchem.2021.682862 PMC8220148 49. Montaigne D Butruille L Staels B PPAR control of metabolism and cardiovascular functions Nat. Rev. Cardiol. 2021 18 809 823 10.1038/s41569-021-00569-6 34127848 Montaigne, D., Butruille, L. & Staels, B. PPAR control of metabolism and cardiovascular functions. Nat. Rev. Cardiol. 18 34127848 10.1038/s41569-021-00569-6 50. Gold PW The PPARG system in major depression: Pathophysiologic and therapeutic implications Int. J. Mol. Sci. 2021 22 9248 10.3390/ijms22179248 34502154 PMC8430913 Gold, P. W. The PPARG system in major depression: Pathophysiologic and therapeutic implications. Int. J. Mol. Sci. 22 34502154 10.3390/ijms22179248 PMC8430913 51. Ran Y Integrated investigation and experimental validation of PPARG as an oncogenic driver: Implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma Front. Pharmacol. 2023 14 1298341 10.3389/fphar.2023.1298341 38044948 PMC10690586 Ran, Y. et al. Integrated investigation and experimental validation of PPARG as an oncogenic driver: Implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma. Front. Pharmacol. 14 38044948 10.3389/fphar.2023.1298341 PMC10690586 52. Adams CM Clark-Garvey S Porcu P Eischen CM Targeting the Bcl-2 family in B cell lymphoma Front. Oncol. 2019 9 638 10.3389/fonc.2018.00636 30671383 PMC6331425 Adams, C. M., Clark-Garvey, S., Porcu, P. & Eischen, C. M. Targeting the Bcl-2 family in B cell lymphoma. Front. Oncol. 9 30671383 10.3389/fonc.2018.00636 PMC6331425 53. Singh R Letai A Sarosiek K Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins Nat. Rev. Mol. Cell Biol. 2019 20 175 193 10.1038/s41580-018-0089-8 30655609 PMC7325303 Singh, R., Letai, A. & Sarosiek, K. Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 20 30655609 10.1038/s41580-018-0089-8 PMC7325303 54. Tessoulin B BCL2-family dysregulation in B-cell malignancies: From gene expression regulation to a targeted therapy biomarker Front. Oncol. 2019 9 645 10.3389/fonc.2018.00645 30666297 PMC6330761 Tessoulin, B. et al. BCL2-family dysregulation in B-cell malignancies: From gene expression regulation to a targeted therapy biomarker. Front. Oncol. 9 30666297 10.3389/fonc.2018.00645 PMC6330761 55. Zhang L Lu Z Zhao X Targeting Bcl-2 for cancer therapy Biochim. Biophys. Acta Rev. Cancer 2021 1876 188569 10.1016/j.bbcan.2021.188569 34015412 Zhang, L., Lu, Z. & Zhao, X. Targeting Bcl-2 for cancer therapy. Biochim. Biophys. Acta Rev. Cancer 1876 34015412 10.1016/j.bbcan.2021.188569 ",
  "metadata": {
    "Title of this paper": "Targeting Bcl-2 for cancer therapy",
    "Journal it was published in:": "Scientific Reports",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491499/"
  }
}